71-58-9

• 常用中文名：安宫黄体酮
• 常用英文名：Medroxyprogesterone 17-acetate
• CAS号：71-58-9
• 分子式：C₂₄H₃₄O₄
• 分子量：386.524
• 相关类别： 原料药 激素及调节内分泌功能类药 雌激素及孕激素类药
• 发布时间：2018-02-05 08:00:00
• 更新时间：2024-01-03 20:09:06
• Medroxyprogesterone醋酸盐是孕酮受体激动剂,是合成的人激素孕酮变体。

名称

• 中文名: 醋酸甲羟孕酮
• 英文名: medroxyprogesterone acetate
• 中文别名: 甲羟孕酮17-乙酸酯; 醋酸甲羟孕酮; 17α-乙酰氧基-6α-甲基黄体酮; 安宫黄体酮; 安宫黄体酮; 甲孕酮
• 英文别名: G-Farlutal; Pregn-4-ene-3,20-dione, 17-hydroxy-6α-methyl-, acetate (8CI); Progesterone, 17-hydroxy-6α-methyl-, acetate; 17a-Hydroxy-6a-methylpregn-4-ene-3,20-dione acetate; 17a-Hydroxy-6a-methylprogesterone acetate; 17-Acetoxy-6α-methylprogesterone; MFCD00010483; Medroxyprogesterone 17-acetate; pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6a)-; (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate; 17α-Acetoxy-6-α-methylpregn-4-ene-3,20-dione; Provest; Sodelut G; EINECS 200-757-9; Pregn-4-ene-3,20-dione, 17- (acetyloxy)-6-methyl-, (6α)-; (6α)-6-Methyl-3,20-dioxopregn-4-en-17-yl acetate; 6α-Methyl-17α-hydroxyprogesterone acetate; 6a-Methyl-4-pregnene-3,20-dion-17a-ol acetate; Medroxiprogesteron Acetate; 17α-Acetoxy-6α-methylprogesterone; (6a)-6-methyl-3,20-dioxopregn-4-en-17-yl acetate; 17α-acetoxy-6α-methyl-pregn-4-ene-3,20-dione; 6α-Methyl-17α-acetoxypregn-4-ene-3,20-dione; 17α-Hydroxy-6α-methylpregn-4-ene-3,20-dione acetate; Gestoral; 17a-Acetoxy-6a-methylpregn-4-ene-3,20-dione; Medroxyprogesterone acetate; Gestapuron; 6a-Methyl-17a-acetoxyprogesterone; 6α-Methyl-17α-acetoxyprogesterone; 6α-Methyl-4-pregnene-3,20-dion-17α-ol acetate; 6α-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-; 17a-Acetoxy-6a-methylprogesterone; Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6α)-; 17α-hydroxy-6α-methylprogesterone acetate; 6α-Methyl-17-acetoxyprogesterone; MAP; 17α-Hydroxy-6-α-methylprogesterone acetate; Medroxyprogesterone (acetate)

物化性质

• 密度: 1.1±0.1 g/cm3
• 沸点: 496.4±45.0 °C at 760 mmHg
• 熔点: 206-207 °C(lit.)
• 分子式: C₂₄H₃₄O₄
• 分子量: 386.524
• 闪点: 213.2±28.8 °C
• 精确质量: 386.245697
• PSA: 60.44000
• LogP: 4.11
• 外观性状: 白色粉末
• 蒸汽压: 0.0±1.3 mmHg at 25°C
• 折射率: 1.539
• 储存条件:

  本品应密封阴凉干燥避光保存。

• 稳定性: Stable, but weakly air and light sensitive. Incompatible with strong oxidizing agents.
• 水溶解性: <0.1 g/100 mL at 23 ºC
• 分子结构:

  1、 摩尔折射率：106.71

  2、 摩尔体积（cm³/mol）：340.8

  3、 等张比容（90.2K）：873.9

  4、 表面张力（dyne/cm）：43.2

  5、 极化率（10-24cm3）：42.30

• 计算化学:

  1.疏水参数计算参考值（XlogP）:无

  2.氢键供体数量:0

  3.氢键受体数量:4

  4.可旋转化学键数量:3

  5.互变异构体数量:10

  6.拓扑分子极性表面积60.4

  7.重原子数量:28

  8.表面电荷:0

  9.复杂度:767

  10.同位素原子数量:0

  11.确定原子立构中心数量:7

  12.不确定原子立构中心数量:0

  13.确定化学键立构中心数量:0

  14.不确定化学键立构中心数量:0

  15.共价键单元数量:1

• 更多:

  1. 性状：白色

  2. 密度（g/mL,25/4℃）：不确定

  3. 相对蒸汽密度（g/mL,空气=1）：不确定

  4. 熔点（ºC）：206-207 (lit.)

  5. 沸点（ºC,常压）：不确定

  6. 沸点（ºC, 5.2 kPa）：不确定

  7. 折射率：48 ° (C=1, Dioxane)

  8. 闪点（ºC）：不确定

  9. 比旋光度（º）：不确定

  10. 自燃点或引燃温度（ºC）：不确定

  11. 蒸气压（kPa,25 ºC）：不确定

  12. 饱和蒸气压（kPa,60 ºC）：不确定

  13. 燃烧热（KJ/mol）：不确定

  14. 临界温度（ºC）：不确定

  15. 临界压力（KPa）：不确定

  16. 油水（辛醇/水）分配系数的对数值：不确定

  17. 爆炸上限（%,V/V）：不确定

  18. 爆炸下限（%,V/V）：不确定

  19. 溶解性：溶于水和乙醇。

生物活性

• 描述: Medroxyprogesterone醋酸盐是孕酮受体激动剂,是合成的人激素孕酮变体。
• 相关类别:
  信号通路 >> 其他 >> 孕激素受体
  研究领域 >> 内分泌
• 参考文献:

  [1]. Schindler, A.E., et al., Classification and pharmacology of progestins. Maturitas, 2008. 61(1-2): p. 171-80.

  [2]. Lenco, W., M. McKnight, and A.S. Macdonald, Effects of cortisone acetate, methylprednisolone and medroxyprogesterone on wound contracture and epithelization in rabbits. Ann Surg, 1975. 181(1): p. 67-73.

MSDS

模块1. 化学品 1.1 产品标识符 : 醋酸甲羟孕酮 产品名称 1.2 鉴别的其他方法 Depo-provera 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-acetate 6α-Methyl-17α-acetoxyprogesterone 17α-Acetoxy-6α-methylprogesterone 6α-Methyl-17α-hydroxyprogesterone acetate 1.3 有关的确定了的物质或混合物的用途和建议不适合的用途 仅用于研发。不作为药品、家庭或其它用途。 模块2. 危险性概述 2.1 GHS-分类 致癌性 (类别 2) 2.2 GHS 标记要素，包括预防性的陈述 象形图 警示词警告 危险申明 H351怀疑会致癌。 警告申明 预防 P201在使用前获取特别指示。 P202在读懂所有安全防范措施之前切勿操作。 P281使用所需的个人防护设备。 响应 P308 + P313如接触到或有疑虑：求医/ 就诊。 储存 P405存放处须加锁。 处置 P501将内容物/ 容器处理到得到批准的废物处理厂。 2.3 其它危害物 - 无 模块3. 成分/组成信息 3.1 物 质 : Depo-provera 别名 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-acetate 6α-Methyl-17α-acetoxyprogesterone 17α-Acetoxy-6α-methylprogesterone 6α-Methyl-17α-hydroxyprogesterone acetate : C24H34O4 分子式 : 386.52 g/mol 分子量 组分浓度或浓度范围 Medroxyprogesterone acetate - 化学文摘登记号(CAS 71-58-9 No.)200-757-9 EC-编号 模块4. 急救措施 4.1 必要的急救措施描述 一般的建议 请教医生。 向到现场的医生出示此安全技术说明书。 吸入 如果吸入,请将患者移到新鲜空气处。 如呼吸停止,进行人工呼吸。 请教医生。 皮肤接触 用肥皂和大量的水冲洗。 请教医生。 眼睛接触 用水冲洗眼睛作为预防措施。 食入 切勿给失去知觉者通过口喂任何东西。 用水漱口。 请教医生。 4.2 主要症状和影响，急性和迟发效应 据我们所知，此化学，物理和毒性性质尚未经完整的研究。 4.3 及时的医疗处理和所需的特殊处理的说明和指示 无数据资料 模块5. 消防措施 5.1 灭火介质 灭火方法及灭火剂 用水雾,抗乙醇泡沫,干粉或二氧化碳灭火。 5.2 源于此物质或混合物的特别的危害 碳氧化物 5.3 给消防员的建议 如必要的话,戴自给式呼吸器去救火。 5.4 进一步信息 无数据资料 模块6. 泄露应急处理 6.1 作业人员防护措施、防护装备和应急处置程序 使用个人防护用品。 避免粉尘生成。 避免吸入蒸气、烟雾或气体。 保证充分的通风。 人员疏散到安全区域。 避免吸入粉尘。 6.2 环境保护措施 如能确保安全，可采取措施防止进一步的泄漏或溢出。 不要让产品进入下水道。 6.3 泄漏化学品的收容、清除方法及所使用的处置材料 收集和处置时不要产生粉尘。 扫掉和铲掉。 放入合适的封闭的容器中待处理。 6.4 参考其他部分 丢弃处理请参阅第13节。 模块7. 操作处置与储存 7.1 安全操作的注意事项 避免接触皮肤和眼睛。 避免形成粉尘和气溶胶。 在有粉尘生成的地方,提供合适的排风设备。一般性的防火保护措施。 7.2 安全储存的条件,包括任何不兼容性 贮存在阴凉处。 使容器保持密闭，储存在干燥通风处。 7.3 特定用途 无数据资料 模块8. 接触控制和个体防护 8.1 容许浓度 最高容许浓度 没有已知的国家规定的暴露极限。 8.2 暴露控制 适当的技术控制 根据良好的工业卫生和安全规范进行操作。 休息前和工作结束时洗手。 个体防护设备 眼/面保护 带有防护边罩的安全眼镜符合 EN166要求请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟) 检测与批准的设备防护眼部。 皮肤保护 戴手套取 手套在使用前必须受检查。 请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品. 使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手 所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。 身体保护 防渗透的衣服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和数量来选择。 呼吸系统防护 如危险性评测显示需要使用空气净化的防毒面具，请使用全面罩式多功能微粒防毒面具N100型（US ）或P3型（EN 143）防毒面具筒作为工程控制的候补。如果防毒面具是保护的唯一方式，则使用全面罩式送风防毒 面具。 呼吸器使用经过测试并通过政府标准如NIOSH（US）或CEN（EU）的呼吸器和零件。 模块9. 理化特性 9.1 基本的理化特性的信息 a) 外观与性状 形状: 固体 b) 气味 无数据资料 c) 气味阈值 无数据资料 d) pH值 无数据资料 e) 熔点/凝固点 熔点/凝固点: 206 - 207 °C - lit. f) 沸点、初沸点和沸程 无数据资料 g) 闪点 无数据资料 h) 蒸发速率 无数据资料 i) 易燃性(固体,气体) 无数据资料 j) 高的/低的燃烧性或爆炸性限度 无数据资料 k) 蒸气压 无数据资料 l) 蒸汽密度 无数据资料 m) 密度/相对密度 无数据资料 n) 水溶性 无数据资料 o) n-辛醇/水分配系数 无数据资料 p) 自燃温度 无数据资料 q) 分解温度 无数据资料 r) 粘度 无数据资料 模块10. 稳定性和反应活性 10.1 反应性 无数据资料 10.2 稳定性 无数据资料 10.3 危险反应 无数据资料 10.4 应避免的条件 无数据资料 10.5 不相容的物质 强氧化剂, 强碱 10.6 危险的分解产物 其它分解产物 - 无数据资料 模块11. 毒理学资料 11.1 毒理学影响的信息 急性毒性 半数致死剂量 (LD50) 经口 - 大鼠 - > 6,400 mg/kg 备注: 肝脏：其他变化 皮肤刺激或腐蚀 无数据资料 眼睛刺激或腐蚀 无数据资料 呼吸道或皮肤过敏 无数据资料 生殖细胞突变性 无数据资料 致癌性 该产品是或包含被IARC, ACGIH, EPA, 和 NTP 列为致癌物的组分 在动物研究中的有限致癌性证据 IARC: 2B - 第2B组：可能对人类致癌 (Medroxyprogesterone acetate) 生殖毒性 无数据资料 从实验动物的结果看，过度接触能导致生殖紊乱 特异性靶器官系统毒性（一次接触） 无数据资料 特异性靶器官系统毒性（反复接触） 无数据资料 吸入危险 无数据资料 潜在的健康影响 吸入吸入可能有害。 可能引起呼吸道刺激。 摄入如服入是有害的。 皮肤通过皮肤吸收可能有害。 可能引起皮肤刺激。 眼睛可能引起眼睛刺激。 接触后的征兆和症状 据我们所知，此化学，物理和毒性性质尚未经完整的研究。 附加说明 化学物质毒性作用登记: TU5010000 模块12. 生态学资料 12.1 生态毒性 无数据资料 12.2 持久性和降解性 无数据资料 12.3 潜在的生物累积性 无数据资料 12.4 土壤中的迁移性 无数据资料 12.5 PBT 和 vPvB的结果评价 无数据资料 12.6 其它不良影响 无数据资料 模块13. 废弃处置 13.1 废物处理方法 产品 将剩余的和不可回收的溶液交给有许可证的公司处理。 联系专业的拥有废弃物处理执照的机构来处理此物质。 与易燃溶剂相溶或者相混合，在备有燃烧后处理和洗刷作用的化学焚化炉中燃烧 受污染的容器和包装 按未用产品处置。 模块14. 运输信息 14.1 联合国危险货物编号 欧洲陆运危规: -国际海运危规: -国际空运危规: - 14.2 联合国运输名称 欧洲陆运危规: 非危险货物 国际海运危规: 非危险货物 国际空运危规: 非危险货物 14.3 运输危险类别 欧洲陆运危规: -国际海运危规: -国际空运危规: - 14.4 包裹组 欧洲陆运危规: -国际海运危规: -国际空运危规: - 14.5 环境危险 欧洲陆运危规: 否国际海运危规国际空运危规: 否 海洋污染物（是/否）: 否 14.6 对使用者的特别提醒 无数据资料 上述信息视为正确，但不包含所有的信息，仅作为指引使用。本文件中的信息是基于我们目前所知，就正 确的安全提示来说适用于本品。该信息不代表对此产品性质的保证。 参见发票或包装条的反面。 模块 15 - 法规信息 N/A 模块16 - 其他信息 N/A

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : TU5010000 CHEMICAL NAME : (6-alpha)-Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl- CAS REGISTRY NUMBER : 71-58-9 BEILSTEIN REFERENCE NO. : 2066112 LAST UPDATED : 199806 DATA ITEMS CITED : 93 MOLECULAR FORMULA : C24-H34-O4 MOLECULAR WEIGHT : 386.58 WISWESSER LINE NOTATION : L E5 B666 OV MUTJ A1 E1 FV1 FOV1 L1 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Human - woman DOSE/DURATION : 10 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - increased intraocular pressure TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Human - woman DOSE/DURATION : 21 mg/kg TOXIC EFFECTS : Sense Organs and Special Senses (Eye) - increased intraocular pressure TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >6400 mg/kg TOXIC EFFECTS : Liver - other changes TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >900 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >900 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >16 gm/kg TOXIC EFFECTS : Endocrine - adrenal cortex hypoplasia TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >1500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >1500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >5 gm/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 6 gm/kg/30D-I TOXIC EFFECTS : Liver - changes in liver weight Blood - changes in leukocyte (WBC) count Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - phosphatases TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 25 mg/kg TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Skin and Appendages - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 9600 mg/kg/1Y-I TOXIC EFFECTS : Tumorigenic - Carcinogenic by RTECS criteria Skin and Appendages - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 30 mg/kg/26W-I TOXIC EFFECTS : Tumorigenic - neoplastic by RTECS criteria Liver - tumors Skin and Appendages - tumors TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 324 mg/kg/4Y-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Skin and Appendages - tumors TYPE OF TEST : TD - Toxic dose (other than lowest) ROUTE OF EXPOSURE : Intramuscular SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 1240 mg/kg/4Y-I TOXIC EFFECTS : Tumorigenic - equivocal tumorigenic agent by RTECS criteria Skin and Appendages - tumors TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 12 mg/kg SEX/DURATION : female 4 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 3 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 3 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 12 mg/kg SEX/DURATION : female 4 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 4 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 3 mg/kg SEX/DURATION : lactating female 1 day(s) post-birth TOXIC EFFECTS : Reproductive - Maternal Effects - postpartum TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 8570 ug/kg SEX/DURATION : male 4 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 3 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 15 mg/kg SEX/DURATION : female 6 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 3 mg/kg SEX/DURATION : female 3 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 3 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral DOSE : 96 mg/kg SEX/DURATION : female 32 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 3500 ug/kg SEX/DURATION : female 6 week(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 12 mg/kg SEX/DURATION : female 6-20 week(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - behavioral TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Multiple routes DOSE : 27800 ug/kg SEX/DURATION : female 8-14 week(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - abortion TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 20 mg/kg SEX/DURATION : male 10 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 4500 ug/kg SEX/DURATION : female 15-20 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 28950 ug/kg SEX/DURATION : female 30 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 75 mg/kg SEX/DURATION : female 12-22 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 60 mg/kg SEX/DURATION : male 10 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 550 mg/kg SEX/DURATION : female 11 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 112 mg/kg SEX/DURATION : male 28 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 7500 ug/kg SEX/DURATION : female 15-20 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 2800 ug/kg SEX/DURATION : female 14 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 10 mg/kg SEX/DURATION : male 10 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 5 mg/kg SEX/DURATION : female 15-24 day(s) after conception TOXIC EFFECTS : Reproductive - Maternal Effects - parturition TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 1400 ug/kg SEX/DURATION : female 14 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 5 mg/kg SEX/DURATION : lactating female 1 day(s) post-birth TOXIC EFFECTS : Reproductive - Effects on Newborn - physical TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 4500 ug/kg SEX/DURATION : male 18 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 80 mg/kg SEX/DURATION : male 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 45 mg/kg SEX/DURATION : female 13 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Unreported DOSE : 50 mg/kg SEX/DURATION : female 9-22 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - germ cell effects (in offspring) Reproductive - Effects on Newborn - delayed effects TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intrauterine DOSE : 10 mg/kg SEX/DURATION : female 9-21 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 5 mg/kg SEX/DURATION : female 2 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 9000 mg/kg SEX/DURATION : female 7-15 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 30 mg/kg SEX/DURATION : female 9 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 650 mg/kg SEX/DURATION : female 7-19 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant DOSE : 650 mg/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Implant DOSE : 6500 mg/kg SEX/DURATION : female 6-18 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 5 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 5 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 5 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 10 mg/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 2400 ug/kg SEX/DURATION : female 3 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 60 mg/kg SEX/DURATION : female 6 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - breasts, lactation (prior to or during pregnancy) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 25 mg/kg SEX/DURATION : female 27 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Newborn - physical TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 25 mg/kg SEX/DURATION : female 27 day(s) pre-mating TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 100 mg/kg SEX/DURATION : female 27 day(s) pre-mating TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - endocrine system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 75 ug/kg SEX/DURATION : female 2 day(s) pre-mating female 1 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 625 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Administration onto the skin DOSE : 500 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Administration onto the skin DOSE : 50 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 25 ug/kg SEX/DURATION : female 5 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - uterus, cervix, vagina TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 9 mg/kg SEX/DURATION : female 13-15 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - other developmental abnormalities TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 30 mg/kg SEX/DURATION : female 7-9 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 20 ug/kg SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 3 mg/kg SEX/DURATION : female 13-15 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 167 mg/kg SEX/DURATION : female 10 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 267 mg/kg SEX/DURATION : female 16 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - ovaries, fallopian tubes TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 86 mg/kg SEX/DURATION : female 18-60 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Specific Developmental Abnormalities - urogenital system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intramuscular DOSE : 1480 mg/kg SEX/DURATION : male 70 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 12 mg/kg SEX/DURATION : male 60 day(s) pre-mating TOXIC EFFECTS : Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - other effects on male TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 80 ug/kg SEX/DURATION : female 16 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intravenous DOSE : 160 ug/kg SEX/DURATION : female 16 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral DOSE : 9231 ug/kg SEX/DURATION : female 3 day(s) pre-mating TOXIC EFFECTS : Reproductive - Fertility - other measures of fertility MUTATION DATA TYPE OF TEST : DNA inhibition TEST SYSTEM : Human Lymphocyte DOSE/DURATION : 50 umol/L REFERENCE : PSEBAA Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1903/04- Volume(issue)/page/year: 146,401,1974 *** REVIEWS *** IARC Cancer Review:Animal Sufficient Evidence IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,289,1987 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 21,417,1979 IARC Cancer Review:Group 2B IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,289,1987 TOXICOLOGY REVIEW SRCHAA Search. (Australian and New Zealand Assoc. for the Advancement of Science, POB 873, GPO, Sydney, N.S.W., Australia) V.1- 1970- Volume(issue)/page/year: 5,236,1974 TOXICOLOGY REVIEW CCPTAY Contraception. (Geron-X, Inc., POB 1108, Los Altos, CA 94022) V.1- 1970- Volume(issue)/page/year: 12,377,1975 TOXICOLOGY REVIEW COGYAK Clinical Obstetrics and Gynecology. (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1958- Volume(issue)/page/year: 16(4),37,1973 TOXICOLOGY REVIEW AJOGAH American Journal of Obstetrics and Gynecology. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1920- Volume(issue)/page/year: 120,537,1974 TOXICOLOGY REVIEW TJADAB Teratology, The International Journal of Abnormal Development. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 21,225,1980 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5308 No. of Facilities: 41 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 1228 (estimated) No. of Female Employees: 661 (estimated)

安全

• 符号: GHS08
• 信号词: Warning
• 危害声明: H351
• 警示性声明: P281
• 个人防护装备: Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
• 危害码 (欧洲): Xn:Harmful
• 风险声明 (欧洲): R40;R48
• 安全声明 (欧洲): S22-S36/37/39-S45
• 危险品运输编码: 2811.0
• WGK德国: 3
• RTECS号: TU5010000

合成路线

上下游产品

上游产品  9
32634-95-0 809-01-8 3386-01-4 3386-00-3
3496-78-4 520-85-4 108-24-7 1863-39-4
113665-92-2
下游产品  4
3562-63-8 595-33-5 520-85-4 69688-15-9